BAVENCIO avelumab

Drug Class

PD-L1 blocking antibody

Mechanism

Avelumab binds to PD-L1 and blocks the interaction between PD-L1 and PD-1 receptors, releasing PD-L1-mediated inhibition of immune responses.

Approved Indication

Maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) that has not progressed on first-line platinum-containing chemotherapy; treatment of patients with metastatic Merkel cell carcinoma (MCC) and advanced renal cell carcinoma (RCC) in combination with axitinib.

What This Means For Patients

BAVENCIO is not distributed through mainland China's retail pharmacy network. Uwell Cloud can help arrange a purchase channel for this medicine, sourced and dispatched from Hong Kong; clinical administration support in China can be coordinated on request. Availability and eligibility for any specific patient are determined by clinical review.

Regulatory Approvals

• FDA — Approved (2017) — Sources
• EMA — Approved (2017) — Sources

Pivotal Clinical Evidence

• JAVELIN Bladder 100 — Powles et al., N Engl J Med 2020 (NCT02603432) — Sources

Sources

• https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209184s011lbl.pdf
• https://www.ema.europa.eu/en/medicines/human/EPAR/bavencio
• https://doi.org/10.1056/NEJMoa2002788